Latest

Controversial 340B Drug Discounts Linked to Drug Pricing Issues

Pharma companies have been protesting expansion of the federal program that provides deeply discounted prescription drugs to certain hospitals and health providers serving low-income, uninsured patients.

Avoiding a CIA: Analytics and the Search for Dangerous Data

Internal oversight and the tools to remain compliant are critical to companies seeking to avoid corporate integrity agreements (CIAs) or efficiently fulfill existing agreements. In either case, CIAs can be a business advantage, writes Gabriela P. Baron.

Global Harmonization of Customer Data

Cherry Cabading and Mona Rakibe outline how the use of modern data management techniques can help companies see improvements in sales effectiveness, data steward productivity and overall data quality.

PharmExec Videos

New & Noteworthy

Why Pharma Needs to Catch Up On Digital

More pharma companies are reporting that their digital strategies are ineffective compared to other industries. Heath Jackson looks at why this is – and what they need to do about it.

Accelerating Approvals, Revisiting Reimbursement

Excitement over more new treatments for cancer and rare diseases is offset by cringing over prices.

Refining Value in Pharma

Value frameworks are now "sexy". In the US, no fewer than five have emerged since 2015. Leela Barham discusses how the landscape is evolving.

Customer Engagement: A Key Upgrade in Brand Planning for a Multi-Channel World

Gregg Fisher reflects on how brand planning can be enhanced to better serve brand and product managers to deliver on the promises of “customer-centric” and “multi-channel” communications.

Sales & Marketing

Customer Engagement: A Key Upgrade in Brand Planning for a Multi-Channel World

Gregg Fisher reflects on how brand planning can be enhanced to better serve brand and product managers to deliver on the promises of “customer-centric” and “multi-channel” communications.

Decoding the Disruption: Making Meaningful Marketing Out of Top Trends

Separating the meaningful from the merely novel, Bill Drummy outlines his Top Ten digital marketing trends for 2017.

Beyond KOL Marketing: Tapping Digital Opinion Influencers

Pharma has long recognized the power of key opinion leaders, but with HCPs and patients now acquiring much of their information online, there is a new opportunity for "digital opinion influencers".

Featured E-Books

Bright Skies, Big Challenges: Orphan Drugs and Rare Diseases

From the editors of Pharmaceutical Executive, check out the latest e-book discussing the state and future of Rare and Orphan Diseases. Download the e-book.

 

Securing the Global Supply Chain: Strategies for Operational Excellence

Strategic management of the supply chain is vital to winning with customers. Cost and quality are important, but they are not the only things customers care about: New services, flexibility in  relationships, supply reliability, and creatively overcoming obstacles in delivery of products are also core values. Pharmaceutical product portfolios and customers are becoming more complex. To stay ahead, customer-focused supply-chain capabilities is becoming an increasingly crucial part of a company’s competitive advantage. Download the e-book.

 

The Changing Contours of Drug Commercialization

"The Changing Contours of Drug Commercialization," a new e-book from the editors of Pharmaceutical Executive, sheds light on solutions and strategies uniquely within a manufacturer's own sphere of control that can help navigate the often unforgiving transition from registration to the real-world battle for clinical acceptance and market share. Download the e-book.

 

 

View all e-books

PEspeaks

Will UK Industry Show a United Front on Pricing?

Tensions are becoming clear within industry as it faces what might yet be the toughest negotiations on pricing with the UK government. Leela Barham reports.

News Sales Reps for a New Era

The era of complex biological drugs requires sales reps with more advanced knowledge, write Bagrat Lalayan.

The UK's "Decelerated" Access Review

The UK's proposed Accelerated Access Review is being dogged by delay and disappointment, writes Leela Barham.

Pediatric, Veterinary Oncologists Call for More Comparative Research

Dogs and kids both spontaneously develop a number of cancers, making it a no-brainer for those on both sides of the disease to work together in finding new therapies.

Compliance Top of Mind

There is never a lack of legal or regulatory issues to keep track of—and worry about—in the life sciences industry. The articles from Pharmaceutical Executive provide a look at the latest in compliance for marketing, labeling, and export control, as well as offer tips to stay compliant in the coming years.
 

Read More.

Interviews

Improving Patients’ Lives and Boosting Mature Product Portfolios

Q&A with Merck KGaA’s Simon Sturge spotlights the development of one injection device that is helping change the treatment-adherence landscape.

Executive Roundtable: Where is Your Physician?

A panel of biopharma executives discuss market access and the changing dynamics in reaching physicians and healthcare professionals.

Compliance in the Pharmaceutical Industry: A Marketer's Perspective

Interacting with HCPs is fraught with compliance challenges. This article takes a deep dive the implications of compliance for marketers in a world where new technologies being created every day.

Labeling: Not Just a Technical Issue

At recent the BETHEEXPERT 2017 event in Budapest, we asked Romuald Braun what pharma should be focusing on with regard to its labeling activities.

Regulatory

Avoiding a CIA: Analytics and the Search for Dangerous Data

Internal oversight and the tools to remain compliant are critical to companies seeking to avoid corporate integrity agreements (CIAs) or efficiently fulfill existing agreements. In either case, CIAs can be a business advantage, writes Gabriela P. Baron.

Accelerating Approvals, Revisiting Reimbursement

Excitement over more new treatments for cancer and rare diseases is offset by cringing over prices.

The UK's "Decelerated" Access Review

The UK's proposed Accelerated Access Review is being dogged by delay and disappointment, writes Leela Barham.

Refining Value in Pharma

Value frameworks are now "sexy". In the US, no fewer than five have emerged since 2015. Leela Barham discusses how the landscape is evolving.

From the Editor

The 1, 2, 3’s of VBCs

As we step further into the waters of value-based contracting arrangements, lessons learned must be shared—including the role of the patient in the equation.

Talent That Takes You into the Future

There's no shortage of talent, expertise and passion in the biopharma industry. It's time for that talent to shine, writes Lisa Henderson.

Don’t be the Next #Hashtag

Recent PR disasters in other industries raise an important reputational question that can apply to pharma as well: do you want to be someone that works the system or improves the system?

lorem ipsum